# Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus

Study · id `cardio:ct-nct04484259` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04484259](<https://clinicaltrials.gov/study/NCT04484259>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04484259

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 105 participants.

## Technical summary

Registry record NCT04484259. Randomized; no masking; primary purpose treatment. Start 2021-03-31 (actual); primary completion 2024-01-29 (actual). Results posted on 2025-03-30.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 105 participants (enrolled count; ClinicalTrials.gov record NCT04484259, source copy `cardio:ctgov-nct04484259-2025-03-30`, retrieved 2026-10-26)
- Started: 2021-03-31 (actual) (ClinicalTrials.gov record NCT04484259, source copy `cardio:ctgov-nct04484259-2025-03-30`, retrieved 2026-10-26)
- Primary completion: 2024-01-29 (actual) (ClinicalTrials.gov record NCT04484259, source copy `cardio:ctgov-nct04484259-2025-03-30`, retrieved 2026-10-26)
- Completion: 2024-06-15 (actual) (ClinicalTrials.gov record NCT04484259, source copy `cardio:ctgov-nct04484259-2025-03-30`, retrieved 2026-10-26)
- Results first posted: 2025-03-30 (ClinicalTrials.gov record NCT04484259, source copy `cardio:ctgov-nct04484259-2025-03-30`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04484259, source copy `cardio:ctgov-nct04484259-2025-03-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04484259-2025-03-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus
- Acronym: OPTIMUS-7
- Condition: Diabetes Mellitus, Type 2
- Condition: Coronary Artery Disease
- Intervention (Drug): Ticagrelor monotherapy
- Intervention (Drug): Ticagrelor plus aspirin
- Intervention (Drug): Clopidogrel with aspirin
- Lead sponsor: University of Florida
- Lead sponsor class: OTHER
- Collaborator: AstraZeneca
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: University of Florida (`cardio:org-university-of-florida`)
- Registry lists this organization as a collaborator: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: d1bb6d27d6aaad8789c738b55a12b738e0733eb992fc96a474e7e8c82ecc5d67
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
